Taro gets bad news
This article was originally published in The Tan Sheet
Executive Summary
Two class action suits allege Securities Exchange Act violations by generics firm Taro Pharmaceutical Industries. Suits say the company failed to disclose "adverse factors that were having a negative impact on Taro's financial performance" such as the "increased competitive pressures" the firm was experiencing in the generic drugs business. Philadelphia-based law firm Berger & Montague and New York-based firm Abbey Gardy allege that Taro disregarded hefty costs to develop its branded Rx drug business. Both complaints are filed on behalf of all Taro securities purchasers from Feb. 20 2003 to July 29, 2004...
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.